Jeanne Penn Takes on VP Role at Cambridge Healthcare Research
Jeanne Penn has officially joined Cambridge Healthcare Research as the Vice President for US Commercial at Solici, the company’s competitive intelligence division. This appointment is a major milestone in the company's strategy to expand within the US healthcare landscape.
Enhancing the Solici Team
Brendan Walkden, the Head of Solici, shared his excitement about Jeanne joining the team, emphasizing her vast industry experience and the strategic perspective she brings at such a crucial time for the business. He indicated that Jeanne’s collaboration is essential as the company navigates through this vital growth phase.
Jeanne's Professional Journey
Jeanne comes with decades of experience in delivering market insights for the biopharmaceutical sector. Based in Boston, she has held significant positions at Genzyme and EMD Serono, where she managed competitive intelligence, market research, and brand forecasting across various therapeutic areas. Although her expertise covers multiple fields, she has a profound passion for rare diseases.
Consulting Background
Beyond her corporate positions, Jeanne has worked with consulting firms like DRG, Lifescience Dynamics, and Prescient Healthcare Group. She has effectively led teams in providing top-notch analysis to numerous US clients, showcasing her abilities as both a facilitator and a strategic leader.
A Commitment to Empowering Others
Recognized as a Luminary by the Healthcare Businesswomen's Association for her two-decade-long commitment to empowering women in the workplace, Jeanne exemplifies both leadership and dedication. On a personal note, she enjoys a fulfilling life with her spouse and two adult children.
The Future of Cambridge Healthcare Research
Stephen Galt, the Chief Commercial Officer at Cambridge Healthcare Research, expressed enthusiasm about Jeanne joining the team. He emphasized her remarkable leadership skills and expertise in building high-performance teams, which will help propel the company’s growth. With Jeanne aboard, CHR is set to strengthen its commercial strategies in the US and solidify its market position even further.
About Solici
Cambridge Healthcare Research specializes in delivering strategic decision support across the pharmaceutical, medical device, and consumer healthcare industries. The consultancy works closely with partners to help them navigate complex commercial decisions regarding asset commercialization and product strategy.
Grasping Market Dynamics
As the strategic competitive intelligence division of Cambridge Healthcare Research, Solici plays an essential role in providing decision-makers with in-depth insights into the healthcare and life sciences sectors. The goal is to deliver vital commercial intelligence that empowers clients to make informed choices and map out the best paths forward.
The Team's Drive for Innovation
The team at Solici is dedicated to healthcare innovation. Their assessments of market dynamics and understanding of key trends among prescribers, regulators, and payers enable clients to gain the insights necessary to confront challenges effectively.
Frequently Asked Questions
Who is Jeanne Penn and what is her new role?
Jeanne Penn has been appointed as Vice President, US Commercial for Solici, a division of Cambridge Healthcare Research.
What experience does Jeanne bring to Solici?
Jeanne offers extensive experience in the biopharmaceutical industry, providing insights and strategies from her roles at Genzyme and EMD Serono, among others.
What is the mission of Cambridge Healthcare Research?
Cambridge Healthcare Research is focused on providing strategic decision support, assisting clients in navigating complex commercial challenges and opportunities within the healthcare sector.
How does Solici support the healthcare industry?
Solici offers vital competitive intelligence and market insights, enabling healthcare decision-makers to make informed choices based on thorough data analysis.
Why is Jeanne’s appointment significant?
Her appointment is significant as it underscores Cambridge Healthcare Research's strategy aimed at boosting growth and strengthening its position in a competitive healthcare environment.
